Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$190.74 +0.5%	$187.10	$163.81 ▼ $218.66	$335.21B	0.48	6.29 million shs	5.59 million shs
LLY Eli Lilly and Company	$787.00 +1.2%	$767.12	$677.09 ▼ $972.53	$737.02B	0.4	3.67 million shs	2.70 million shs
NVO Novo Nordisk A/S	$69.80 +0.2%	$70.25	$57.00 ▼ $143.49	$310.94B	0.64	7.29 million shs	5.37 million shs
NVS Novartis	$122.95 +1.0%	$115.63	$96.06 ▼ $124.45	$257.04B	0.59	1.58 million shs	1.19 million shs
PFE Pfizer	$25.56 -0.2%	$23.82	$20.92 ▼ $31.54	$145.66B	0.58	41.80 million shs	38.34 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.15%	-0.17%	-0.15%	+5.44%	+13.87%
LLY Eli Lilly and Company	+0.66%	+0.18%	+1.03%	+3.50%	-15.26%
NVO Novo Nordisk A/S	+0.46%	-0.31%	-6.79%	+6.86%	-51.35%
NVS Novartis	-0.25%	-1.02%	+3.20%	+17.07%	+12.70%
PFE Pfizer	+1.51%	+2.32%	+9.63%	+13.82%	-8.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.947 of 5 stars	3.4	5.0	3.3	3.9	4.0	1.7	1.3
LLY Eli Lilly and Company	4.98 of 5 stars	4.4	4.0	3.3	4.0	3.0	1.7	1.9
NVO Novo Nordisk A/S	4.6896 of 5 stars	4.1	5.0	2.5	0.0	2.4	0.0	3.1
NVS Novartis	1.7989 of 5 stars	1.0	3.0	2.5	0.0	3.3	0.0	1.9
PFE Pfizer	4.977 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	10.77% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,011.61	28.54% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	60.46% Upside
NVS Novartis	2.00	Hold	$123.67	0.58% Upside
PFE Pfizer	2.45	Hold	$28.55	11.70% Upside

Current Analyst Ratings Breakdown

Latest PFE, LLY, NVS, ABBV, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.98	$15.01 per share	12.71	$1.90 per share	100.39
LLY Eli Lilly and Company	$45.04B	16.56	$14.41 per share	54.63	$15.03 per share	52.36
NVO Novo Nordisk A/S	$42.12B	7.40	$3.91 per share	17.85	$4.66 per share	14.98
NVS Novartis	$50.32B	5.16	$10.81 per share	11.37	$21.59 per share	5.69
PFE Pfizer	$63.63B	2.28	$4.35 per share	5.87	$15.62 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	81.17	13.64	1.28	7.31%	412.03%	13.11%	7/31/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	64.04	25.29	1.14	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.65	14.98	1.36	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.21	13.96	1.67	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.52	8.44	0.93	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, LLY, NVS, ABBV, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.89	N/A	N/A	N/A	$77.51 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.44%	N/A	279.15%	53 Years
LLY Eli Lilly and Company	$6.00	0.76%	N/A	48.82%	11 Years
NVO Novo Nordisk A/S	$1.64	2.35%	N/A	48.52%	N/A
NVS Novartis	$2.60	2.11%	N/A	40.63%	N/A
PFE Pfizer	$1.72	6.73%	N/A	124.64%	16 Years

Latest PFE, LLY, NVS, ABBV, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
LLY Eli Lilly and Company	2.18	1.37	1.06
NVO Novo Nordisk A/S	0.70	0.74	0.56
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, LLY, NVS, ABBV, and NVO Headlines

Recent News About These Companies

Pfizer Earnings Preview: What to Expect

5 hours ago | msn.com